Through studies of HER2-positive breast cancer mouse models and patients, it was found that the intestinal microbiota directly affects the efficacy of trastuzumab, and fecal bacteria transplanted from FMT-R mice into HER2 + breast cancer mice reproduced the patient response to trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.